IMTX - Immatics N.V.
IEX Last Trade
7.02
-0.160 -2.279%
Share volume: 1,746
Last Updated: Thu 26 Dec 2024 04:30:26 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$7.18
-0.16
-2.23%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.65%
1 Month
-6.46%
3 Months
-39.83%
6 Months
-40.83%
1 Year
-28.28%
2 Year
-16.57%
Key data
Stock price
$7.02
DAY RANGE
$7.00 - $7.20
52 WEEK RANGE
$6.99 - $13.75
52 WEEK CHANGE
-$34.80
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Harpreet Singh-Jasuja
Region: US
Website: immatics.com
Employees: 260
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: immatics.com
Employees: 260
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Immatics N.V. focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited.
Recent news